Last reviewed · How we verify
NCT05388786
Complications and Adverse Events in Lymphadenectomy in the Inguinal Area
trial testing Delphi Questionnaire in Consensus Development in 200 participants. Status unknown.
30 June 2024
Quick facts
| Lead sponsor | University of Southern California |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 June 2023 |
| Primary completion | 30 June 2024 |
| Estimated completion | 15 December 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Delphi Questionnaire
Conditions studied
- Consensus Development — all drugs for Consensus Development →
Sponsor
University of Southern California
Who can join
18 and older, any sex, with Consensus Development. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators aim to create an effective and accurate method to report, define, and classify complications and adverse events during and after Inguinal lymph node dissection (ILND) as part of the staging and treatment for penile cancer, vulvar cancer, and melanoma. In turn, this will become an objective, efficient, and reproducible tool to facilitate comparisons across surgical approaches, techniques, and surgeons.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Complications and adverse events in lymphadenectomy of the inguinal area: worldwide expert consensus.
Sotelo R, Sayegh AS, Medina LG, Perez LC, et al · · 2024 · cited 6× · PMID 38987232 · DOI 10.1093/bjsopen/zrae056
Verify or expand the search:
- PubMed search for NCT05388786
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Delphi Questionnaire
Trials testing the same drug.
- NCT07420946 — Mechanical Insufflation-Exsufflation in Critically Ill Patients · not yet recruiting
- NCT06552312 — A Modified Delphi for ECPR Post Resuscitation Care · active not recruiting
- NCT06370338 — Cardiothoracic Critical Care as Subspecialty and Its Core Competencies · recruiting
- NCT05373966 — Robotic Radical Nephroureterectomy Delphi Consensus · completed
- NCT05382455 — Preferred Reporting Items for Systematic Reviews and Meta-Analyses - Artificial Intelligence Extension · unknown
Other recruiting trials for Consensus Development
Currently open trials in the same condition.
- NCT06370338 — Cardiothoracic Critical Care as Subspecialty and Its Core Competencies · recruiting
Other University of Southern California trials
Trials by the same sponsor.
- NCT07288463 — Hearing Loss and Genetic Risks for Alzheimer's Disease and Related Dementia · NA · not yet recruiting
- NCT05914233 — Non-invasive Ultrasound Retinal Stimulation for Vision Restoration · NA · not yet recruiting
- NCT06163664 — Role of ChatGPT in Vestibular Schwannoma Management · NA · withdrawn
- NCT07332312 — A Culturally Informed Patient Navigation Program (CFPN) to Reduce Delays Between Diagnosis and Treatment in American Ind · NA · not yet recruiting
- NCT07290478 — Encouraging Older Adults and Adults With Serious Illness to Designate a Health Care Proxy · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05388786 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Southern California
- Last refreshed: 20 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05388786.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing